```html

Uterine (Endometrial) Cancer – Comprehensive Medical Guide

Overview

Uterine cancer, most commonly referred to as endometrial cancer, originates in the lining (endometrium) of the uterus. It is the **most common gynecologic malignancy in the United States** and accounts for about 6% of all cancers in women.

• Incidence: In 2024, the American Cancer Society estimates ~66,000 new cases in the U.S., with ~13,000 deaths.
• Age: The median age at diagnosis is 62 years; about 80% of cases occur after menopause.
* Geography: Higher rates in North America, Europe, and parts of Asia; lower rates in sub‑Saharan Africa.
• Who it affects: Women of any ethnicity, but higher incidence among White and Black women. Certain genetic syndromes (e.g., Lynch syndrome) dramatically increase risk.

Most endometrial cancers are “type I” – estrogen‑dependent, low‑grade tumors that have a good prognosis when caught early. A smaller “type II” group (e.g., serous carcinoma) is not estrogen driven, is more aggressive, and often presents at a later stage.

Symptoms

Early-stage disease frequently produces abnormal uterine bleeding, which makes it one of the easier cancers to detect. However, symptoms can vary.

Common Symptoms

• Abnormal uterine bleeding: Spotting or bleeding between periods, heavier than usual menstrual flow, or post‑menopausal bleeding (any bleeding after 12 months of menopause).
• Painful intercourse (dyspareunia): May result from tumor involvement of the cervical canal.
• Pelvic pain or pressure: Persistent dull ache in the lower abdomen or pelvis.
• Unexplained weight loss: Particularly with more advanced disease.
• Fluid discharge: Watery or mucus‑like vaginal discharge unrelated to infection.

Less Common / Advanced‑Stage Symptoms

• Swelling or a palpable mass in the abdomen.
• Leg swelling or deep‑vein thrombosis (clot) from tumor pressure on pelvic veins.
• Changes in bowel habits (constipation, diarrhea) if the tumor invades the rectum.
• Persistent fatigue or anemia due to chronic blood loss.

Because abnormal bleeding is the hallmark sign, any post‑menopausal bleeding should prompt a medical evaluation.

Causes and Risk Factors

Endometrial cancer develops when DNA in endometrial cells mutates and the normal growth‑regulating processes break down. Several factors increase the chance of such mutations.

Hormonal Influences

• Unopposed estrogen exposure: Long‑term use of estrogen‑only hormone therapy, early menarche, late menopause, or polycystic ovary syndrome (PCOS) increase estrogen without the counterbalancing effect of progesterone.
• Obesity: Adipose tissue converts androgen to estrogen; women with a BMI ≥ 30 have a 2‑3‑fold higher risk.
• Nulliparity or infertility: Women who never have a full‑term pregnancy retain more menstrual cycles, extending estrogen exposure.

Genetic and Familial Factors

• Lynch syndrome (hereditary non‑polyposis colorectal cancer): 40‑60% lifetime risk of endometrial cancer.
• BRCA1/BRCA2 mutations: Slightly increased risk, especially when combined with other factors.
• Family history of endometrial or colorectal cancer.

Other Medical Conditions

• Diabetes mellitus (insulin resistance may promote tumor growth).
• Hypertension (often co‑existent with obesity).
• History of tamoxifen use for breast cancer (tamoxifen has estrogenic effects on the uterus).

Lifestyle & Environmental Factors

• Smoking – paradoxically reduces risk for type I disease but increases risk for aggressive type II.
• Physical inactivity – contributes to obesity and insulin resistance.
• Diet high in saturated fats and low in fruits/vegetables.

Diagnosis

Evaluation begins with a thorough history and pelvic exam, followed by targeted tests to confirm cancer, determine stage, and guide treatment.

Initial Investigations

• Transvaginal ultrasound (TVUS): Measures endometrial thickness; >5 mm in post‑menopausal women is suspicious.
• Endometrial biopsy: Office‑based Pipelle or dilatation‑and‑curettage (D&C) obtains tissue for pathology – the gold standard for diagnosis.

Staging Tests (once cancer is confirmed)

1. Pelvic MRI: Best for assessing myometrial invasion and cervical involvement.
2. CT scan of chest/abdomen/pelvis: Detects distant metastases (lung, liver, lymph nodes).
3. PET‑CT: Useful in high‑risk or recurrent disease to locate occult metastases.
4. Laparoscopic surgical staging: May include sentinel lymph node mapping to evaluate nodal spread.

Pathology & Molecular Profiling

Modern guidelines (NCCN, 2024) recommend molecular classification (POLE ultramutated, microsatellite instability‑high, copy‑number low, copy‑number high) because it predicts prognosis and can influence adjuvant therapy decisions.

Treatment Options

Treatment is individualized based on stage, histology, molecular subtype, patient age, comorbidities, and fertility desires.

Surgical Management

• Total hysterectomy with bilateral salpingo‑oophorectomy (TH‑BSO): Standard for most women with early‑stage disease.
• Fertility‑preserving surgery: For select stage IA, grade 1 tumors, high‑dose progestin therapy may be used instead of hysterectomy.
• Sentinel lymph node (SLN) mapping: Minimally invasive method to assess nodal spread, reducing lymphedema risk.
• Robotic or laparoscopic approaches: Offer shorter hospital stays and faster recovery.

Radiation Therapy

• External beam radiation therapy (EBRT): Often used post‑operatively for high‑risk stage I–II or as primary treatment when surgery is contraindicated.
• Vaginal brachytherapy: Delivers high‑dose radiation to the vaginal cuff; effective for reducing local recurrence.

Systemic Treatments

• Hormonal therapy: Progestins (medroxyprogesterone acetate, megestrol) for low‑grade, hormone‑receptor‑positive tumors or for fertility preservation.
• Chemotherapy: Platinum‑taxane regimens (carboplatin + paclitaxel) are standard for stage III–IV or high‑grade type II disease.
• Targeted therapy & immunotherapy:
  • PD‑1 inhibitors* (e.g., pembrolizumab) for MSI‑high or dMMR tumors.
  • Trastuzumab* for HER2‑positive serous carcinoma.

Supportive & Lifestyle Measures

• Weight management and regular exercise improve outcomes and reduce recurrence risk.
• Nutrition counseling (high‑fiber, low‑saturated‑fat diet).
• Smoking cessation programs.
• Psychosocial support – counseling, survivor groups, and fertility counseling when applicable.

Living with Uterine Cancer (Endometrial Cancer)

Adjusting to a cancer diagnosis involves physical, emotional, and practical considerations.

Post‑treatment Follow‑up

• First 2 years: Physical exam and pelvic imaging every 3–6 months.
• Years 3‑5: Visits every 6–12 months.
• After 5 years: Annual exams, unless symptoms recur.

Managing Side Effects

• Pelvic radiation: Vaginal dryness – use lubricants or estrogen creams (if not contraindicated).
• Chemotherapy: Nausea – anti‑emetics; neuropathy – dose adjustments, gabapentin.
• Surgery: Lymphedema risk – compression garments, physiotherapy.

Emotional Health

Feelings of anxiety, depression, or grief are common. Resources include:

• National Cancer Institute’s Cancer Support Community.
• American Cancer Society’s “Hope & Healing” program.
• Local survivor support groups (often offered through hospitals).

Fertility & Sexual Health

• If fertility was preserved, discuss timing of assisted reproductive technologies.
• Open communication with partners; pelvic floor therapy can improve sexual function.

Practical Tips

• Maintain a medication list and share it with all providers.
• Use a health‑tracking app for symptoms, appointments, and test results.
• Plan for potential work‑related accommodations during treatment.

Prevention

While not all cases are preventable, steps can lower risk substantially.

• Maintain a healthy weight: Aim for BMI < 25; even modest weight loss (~5–10% of body weight) reduces estrogen production from fat.
• Regular physical activity: At least 150 minutes of moderate‑intensity aerobic exercise per week.
• Balanced diet: High in fruits, vegetables, whole grains, and low in red meat and processed foods.
• Limit unopposed estrogen exposure:
  • If hormone therapy is needed, use combined estrogen‑progestin rather than estrogen alone.
  • Manage PCOS with appropriate medical therapy.
• Screen high‑risk women: Annual transvaginal ultrasound or endometrial sampling for women with Lynch syndrome, BRCA mutations, or a strong family history.
• Take prescribed medications as directed: For women on tamoxifen, discuss periodic gynecologic surveillance with your oncologist.

Complications

If the disease is left untreated or diagnosed at an advanced stage, several serious complications can arise.

• Local spread: Invades the myometrium, cervix, bladder, or rectum causing urinary frequency, constipation, or fistulas.
• Metastasis: Common sites include lungs, liver, and bone; leads to organ‑specific symptoms (e.g., shortness of breath, jaundice).
• Severe anemia: Chronic bleeding may require transfusion.
• Thromboembolic events: Cancer‐associated hypercoagulability increases risk of deep‑vein thrombosis and pulmonary embolism.
• Psychological impact: Untreated disease often results in significant distress and reduced quality of life.

When to Seek Emergency Care

---

References: Mayo Clinic, CDC, NIH National Cancer Institute, American Cancer Society, NCCN Guidelines (2024), WHO International Agency for Research on Cancer, Cleveland Clinic.

```